Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (m7) compared to other subtypes of acute myelocytic leukemia

ABSTRACT Acute myelocytic leukemia (AML) is a malignancy that is intrinsically resistant to methotrexate (MTX). AML blasts, when incubated with radiolabeled MTX, form lower amounts of long

chain polyglutamates compared to acute lymphocytic leukemia (ALL) blasts, thus providing an explanation for their lack of responsiveness to MTX. Leukemic blasts obtained from two children

with acute megakaryocytic leukemia (M7 subtype) when incubated with radiolabeled MTX showed increased accumulation of total as well as long chain MTX polyglutamates, comparable to levels

previously demonstrated in another subtype of AML, acute monocytic leukemia (M5), as well as in blasts from patients with pre-B ALL. We suggest that M7-AML patients with blasts showing

increased MTX polyglutamylation might benefit from treatment with MTX. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution

RELEVANT ARTICLES Open Access articles citing this article. * FOLATE METABOLISM: A RE-EMERGING THERAPEUTIC TARGET IN HAEMATOLOGICAL CANCERS * Martha M. Zarou * , Alexei Vazquez *  & G.

Vignir Helgason _Leukemia_ Open Access 11 March 2021 * BMP2K DYSREGULATION PROMOTES ABNORMAL MEGAKARYOPOIESIS IN ACUTE MEGAKARYOBLASTIC LEUKEMIA * Manman Wang * , Tan Zhang *  … Zan Huang

_Cell & Bioscience_ Open Access 15 April 2020 ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only

$21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of

Medicine, Beth Israel Medical Center, New York, NY, USA A Argiris * Department of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA GSA

Longo, W Tong & JR Bertino * Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA R Gorlick & P Steinherz Authors * A Argiris View author publications

You can also search for this author inPubMed Google Scholar * GSA Longo View author publications You can also search for this author inPubMed Google Scholar * R Gorlick View author

publications You can also search for this author inPubMed Google Scholar * W Tong View author publications You can also search for this author inPubMed Google Scholar * P Steinherz View

author publications You can also search for this author inPubMed Google Scholar * JR Bertino View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Argiris, A., Longo, G., Gorlick, R. _et al._ Increased methotrexate polyglutamylation in acute megakaryocytic

leukemia (M7) compared to other subtypes of acute myelocytic leukemia. _Leukemia_ 11, 886–889 (1997). https://doi.org/10.1038/sj.leu.2400647 Download citation * Received: 06 November 1996 *

Accepted: 19 February 1997 * Issue Date: 01 June 1997 * DOI: https://doi.org/10.1038/sj.leu.2400647 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

KEYWORDS * acute myelocytic leukemia * acute megakaryocytic leukemia * methotrexate * polyglutamylation